期刊文献+

纳米混悬液的制备方法及其在药物输送中应用的研究进展 被引量:8

Advances in Study on the Preparation of Nanosuspensions and the Application of Drug Delivery
原文传递
导出
摘要 纳米混悬液系采用少量表面活性剂或其它载体等稳定纯药物粒子所形成的一种亚微米胶体分散体系。纳米混悬液可增大难溶性药物的溶解度,提高药物的有效性和安全性等。通过查阅国内外相关文献,文章就纳米混悬液的制备方法、评价方法及在药物输送中的应用进行了综述。纳米混悬液的制备技术主要有两种,即Bottom up技术和Top down技术。其评价方法主要包括:粒径及粒径分布、Zeta电势、药物晶体状态等。纳米混悬液在各种给药途径中均有优势。 Nanosuspensions consist of the pure poorly water-soluble drug without any matrix material suspended in dispersion. Nanosuspensions not only solve the problems of poor solubility and bioavailability but also improve the efficacy and safety of drugs. The article includes the methods of its preparation, evaluation and application in drug delivery. By consulting relevant literature, the methods of preparation, methods of evaluation and applications in drug delivery are reviewed. The preparation of nanosuspension can be broadly classified into two categories: (i) top-down approache (ii) bottom-up approache. The methods of evaluation are inrolved with particle size and size distribution, Zeta potential, and drug crystal state. Nanosuspension has a lot of advantages in many routes of administration. Nanosuspension as a new drug carrier has broad prospects
出处 《药物生物技术》 CAS CSCD 2011年第4期364-368,共5页 Pharmaceutical Biotechnology
基金 山东省自然科学基金(No.Y2007C141) 山东省中青年科学家奖励基金(No.2007BS02002)
关键词 纳米混悬液 制备方法 评价方法 药物输送 Nanosuspensions, Methods of preparation, Methods of evaluation, Drug delivery
  • 相关文献

参考文献31

  • 1Lipinski C. Poor aqueous solubility - an industry wide prob lem in drug discovery [J].Am Pharm Rev, 2002,5 : 82.
  • 2Serajuddin AT. Salt formation to improve drug solubility[J]. Adv Drug Deliv Rev , 2007,59(7) : 603.
  • 3Binderup E, Bjorkling F, Hjarna PV, etal. EB1627 :a soluble prodrug of the potent anticancer cyanoguanidine CHS828 [J]. Bioorg IVied Chem Lett, 2005,15(10): 2491.
  • 4Jug M,Becirevic-Lacan M, Kwokal A, etal. Influence of cy clodextrin complexation on p-iroxicarn gel formulations[J]. Acta pharm, 2005,55(3) :223.
  • 5Yuan ZP, Chen LJ, Fan LY, etal. Liposomal quercetin effi ciently suppresses growth of solid tumors in murine models [J]. Clin Cancer Res, 2006,12(10) : 3193.
  • 6Shafiq S, Shakeel F, Talegaonkar S, etal. Development and bioavailability assessment of ramipril nanoemulsion formulation[J]. Eur J Pharm Biopharm, 2007,66(2) : 227.
  • 7Liversidge GG, Cundy KC, Bishop J, et al. Surface modified drug nanoparticles[P]. US Patent: 5145684, 8 Sept1992.
  • 8Muller RH, Becker R, Kruss B, etal. Pharmaceutical nano suspensions for medicament administration as system of in creased saturation solubility and rate of solution [P]. US Pa tent:5145684,8 Sept 1992.
  • 9Verma S,Gokhale R,Burgess DJ. A comparative study of top --down and bottom--up approaches for the preparation of micro/nanosuspensions [J]. Int J Pharm, 2009,3811(1- 2):216.
  • 10Birringer R,Gleiter H,Klein HP, et al. Nanocrystalline materials an approach to a novel solid structure with gas- like disorder [J].Phys Lett A, 1984,102(8) : 365.

二级参考文献103

  • 1艾萍,金义光,王林校.药物传送中的纳米混悬液[J].国外医学(药学分册),2005,32(1):61-63. 被引量:9
  • 2张忠义,李红磊,雷正杰.RESS技术在制备药物微粒中的应用[J].中国中药杂志,2006,31(23):1933-1936. 被引量:3
  • 3熊若兰,陆伟根.纳米混悬剂研究进展[J].世界临床药物,2007,28(2):117-121. 被引量:14
  • 4O'Driscoll C M,Griffin B T. Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid-based formulations[J]. Adv Drug Deliv Rev,2008,60(6) :617-624.
  • 5Hauss D J. Oral lipid-based formulations[J]. Adv Drug Deliv Rev,2007,59(7) :667-676.
  • 6Serajuddin A T. Salt formation to improve drug solubility[J]. Adv Drug Deliv Rev,2007,59(7):603-616.
  • 7Kesisoglou F,Panmai S, Wu Yun hui. Nanosizing-oral formulation developmem and biopharmaceutical evaluation[J].Adv Drug Deliv Rev,2007,59(7) : 631-644.
  • 8Amidon G L,Lennernas H,Shah V P,et al. A theoretical basis for a biopharmaceutic drug classification:the correlation of in vitro drug product dissolution and in vivo bioavailability[J].Pharm Res,1995,12(3) :413-420.
  • 9Stella V J, Nti-Addae K W. Prodrug strategies to overcome poor water solubility[J]. Adv Drug Deliv Rev, 2007,59(7):677-694.
  • 10Brewster M E, Loftsson T. Cyclodextrins as pharmaceutical solubilizers[J]. Adv Drug Deliv Rev, 2007,59(7) :645-666.

共引文献68

同被引文献102

引证文献8

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部